Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
1.240
-0.240 (-16.22%)
Streaming Delayed Price
Updated: 3:28 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
27,041
Open
1.250
Bid (Size)
1.240 (1)
Ask (Size)
1.300 (6)
Prev. Close
1.480
Today's Range
1.240 - 1.400
52wk Range
0.0500 - 2.500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
July 17, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
July 17, 2024
Via
ACCESSWIRE
Performance
YTD
+148.00%
+148.00%
1 Month
+18.10%
+18.10%
3 Month
+25.81%
+25.81%
6 Month
+56.96%
+56.96%
1 Year
+422.55%
+422.55%
More News
Read More
Lexaria Preparing For Strategic Growth
July 16, 2024
Via
ACCESSWIRE
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
July 09, 2024
Via
ACCESSWIRE
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
July 08, 2024
Via
ACCESSWIRE
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
June 18, 2024
Via
ACCESSWIRE
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
June 05, 2024
Via
ACCESSWIRE
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
May 23, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
May 23, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
May 21, 2024
Via
ACCESSWIRE
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
May 17, 2024
Via
ACCESSWIRE
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 08, 2024
Via
ACCESSWIRE
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
April 16, 2024
Via
ACCESSWIRE
Lexaria Awarded New Patents
April 02, 2024
Via
ACCESSWIRE
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
ACCESSWIRE
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
April 30, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
April 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
March 14, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 14, 2024
Via
ACCESSWIRE
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
March 07, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
March 05, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
March 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
March 04, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
March 04, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
March 01, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.